



ABN 53 075 582 740

ASX ANNOUNCEMENT
16 February 2012

Bionomics Targets Alzheimer's Disease

- **Bionomics' focus on Alzheimer's disease adds to the Company's diversified portfolio of drug candidates**
- **BNC1881 restores memory in preclinical animal models**
- **Selection of a drug candidate projected later this year**
- **Patent application strengthens the Company's intellectual property portfolio**

16 February 2012: Bionomics Limited (ASX:BNO) today announced that a patent application covering compounds for the improvement of memory in Alzheimer's disease and other neurodegenerative conditions has entered the international phase. These compounds improve cognition through activation of the alpha7 nicotinic acetylcholine receptor.

The patent application is part of Bionomics' growing portfolio of patent filings and know-how in the field.

Bionomics' compounds have the potential to treat Alzheimer's disease by improving memory and also reducing brain tissue inflammation.

One of the proprietary compounds in this patent application is BNC1881, a strong activator of the alpha7 nicotinic acetylcholine receptor. BNC1881 restores memory in preclinical animal models where treatment with a drug (scopolamine) has been used to reduce memory. Further details are shown in the Data Appendix following this announcement.

CEO and Managing Director of Bionomics Dr Deborah Rathjen said "Bionomics is working towards the selection of a drug candidate in this program later this year and protection of our intellectual property is essential to our future partnering strategy."

"This patent application strengthens the Company's intellectual property portfolio in an area of increasing strategic interest for Bionomics".

"In addition to the large and growing Alzheimer's disease market, this therapeutic strategy has potential application for correcting cognitive impairment in Parkinson's disease, Multiple Sclerosis, Schizophrenia and ADHD."

The estimated worldwide costs of dementia, including direct and indirect costs of care, were estimated to be \$604 billion, with an estimated 35.6 million people worldwide affected by dementia in 2010. This number is anticipated to double every 20 years, reaching 65.7 million in 2030 and 115.4 million in 2050. In the US alone an estimated 5.3 million people have AD with 14% of people over 71 years of age affected by AD (*Source: Business Insights, May 2011, Advances in Alzheimer's Disease Drug Discovery: Innovations, challenges, and future directions*).

This program, which targets Alzheimer's disease and other neurodegenerative disorders, confirms Bionomics focus on the discovery of well differentiated drug candidates with potential in the

treatment of serious conditions with significant unmet clinical need, for which large market opportunities exist, and it is a significant addition to Bionomics innovative drug pipeline.

Bionomics' pipeline includes BNC105, a "best in class" vascular disrupting agent for the treatment of solid tumours which is currently in Phase II clinical trials; BNC210, under development for the treatment of anxiety disorders by Bionomics' partner Ironwood Pharmaceuticals; and Kv1.3 blockers for the treatment of Multiple Sclerosis and other autoimmune conditions in partnership with Merck Serono.

Data Appendix




Figure 1: BNC1881 demonstrates a dose dependant reduction of the scopolamine-induced deficit in the rat Novel Object Recognition test. n=12-22 rats. Scopolamine administered by intra-peritoneal injection (i. p.) 20 minutes prior to testing; BNC1881 administered i. p. 60 minutes prior to testing. Vehicle: 25% v/v Cremophor ELP (50°C), 75% v/v NaCl 0.9%. Statistical analysis: Student's T-test; results expressed as mean ± SEM; ** p≤0.01; *** p≤0.001; significantly different to Scopolamine treated rats. Recognition Index: $RI = \frac{tB}{(tA + tB)} \times 100$ where tB is 'time spent exploring object B' and tA is 'time spent exploring Object A'.

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 /
0418 160 425
drathjen@bionomics.com.au

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

The Trout Group
Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com

About Bionomics Limited

Bionomics (ASX: BNO) is a leading international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis.

BNC105, which is undergoing clinical development for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. BNC105 offers blockbuster potential if successfully developed. A clinical program is also underway for the treatment of anxiety disorders and depression based on BNC210, a novel compound which stimulates neurite outgrowth. BNC210 is partnered with Ironwood Pharmaceuticals. Bionomics has a partnered program with Merck Serono for new treatments for multiple sclerosis and other autoimmune disorders.

Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels). MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the

discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system. These platforms underpin Bionomics' established business strategy and Bionomics is committed to securing partners for its key compounds.

For more information about Bionomics, visit www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, BNC210, its Merck Serono alliance, its licensing deal with Ironwood Pharmaceuticals, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.